Promedior is a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis.

Fibrosis is the harmful build-up of scar tissue leading to loss of tissue and organ function. The fibrosis pathology is the hallmark of a number of rare diseases, such as Myelofibrosis, Scleroderma, and Idiopathic Pulmonary Fibrosis, and is a common complication of diabetes including diabetic nephropathy, diabetic retinopathy, and NASH Syndrome, as well as a feature common in many other chronic inflammatory or infectious diseases.  These fibroproliferative diseases are a leading cause of death and disability, and there are currently no approved therapies that can arrest or reverse the fibrosis process.

Promedior is pioneering the development of targeted therapeutics to treat fibroproliferative diseases by regulating the innate immune system’s response to injury.   Promedior’s drug candidates are based on Pentraxin-2, an endogenous human protein that regulates the differentiation of monocyte-lineage cells that control the fibrosis cascade.  The company has extensive research validation of its therapeutic approach with pentraxins and is progressing in human clinical trials.

While the range of potential clinical indications in the fibrosis field is broad, Promedior is focusing its product development in two areas: rare systemic fibrotic diseases such as Myelofibrosis and Idiopathic Pulmonary Fibrosis, and fibrovascular retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and proliferative vitreoretinopathy (PVR).  Promedior is exploring corporate partnerships in some of the larger market indications for fibrosis-related diseases.